Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells.
Among the factors produced at inflammatory sites and those capable of modulating dendritic cell (DC) functions, PGD(2) may be important in the outcome of immune responses. The biological roles for PGD(2) are in part effected through two plasma membrane G protein-coupled receptors: the D prostanoid (DP) receptor and the chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes (CRTH2). In this report, we studied the effects of PGD(2) and of its major physiological metabolite, 15-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)), on the functions of human monocyte-derived DC. First, we show that PGD(2) exerts in vitro chemotactic effects on monocytes via CRTH2 activation while it inhibits the chemokine-driven migration of monocyte-derived DC through DP. We also report that PGD(2) and 15d-PGJ(2) alter the LPS- and allergen-induced DC maturation and enhance the CD80/CD86 ratio on mature DC in a DP- and CRTH2-independent manner. Moreover, PGD(2) and 15d-PGJ(2) strongly reduce the secretion of the Th1 promoting cytokine IL-12 and affect the synthesis of chemokines involved in Th1 cell chemotaxis, particularly CXCL10. Inhibition of cytokine/chemokine secretion implicates at least in part DP, but not CRTH2. The effects exerted by PGD(2) are associated with the phosphorylation of CREB, but do not parallel with the deactivation of the NF-kappa B and mitogen-activated protein kinase pathways. In contrast, 15d-PGJ(2) seems to target other cellular proteins. Finally, in a model of Th CD45RA(+) differentiation induced by allergen- and superantigen-pulsed DC, PGD(2) impacts on the orientation of the immune response by favoring a Th2 response.
Gosset
Philippe
P
Institut National de la Santé et de la Recherche Médicale, Unité 416 and Institut Fédératif de Recherche 17, Institut Pasteur de Lille, Lille, France. Philippe.Gosset@pasteur-lille.fr
Bureau
Fabrice
F
Angeli
Veronique
V
Pichavant
Muriel
M
Faveeuw
Christelle
C
Tonnel
André-Bernard
AB
Trottein
François
F
D002454:Cell Differentiation / Q000276:immunology; D002462:Cell Membrane / Q000378:metabolism; D018925:Chemokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D003713:Dendritic Cells / Q000166:cytology* / Q000378:metabolism / Q000502:physiology; D006131:Growth Inhibitors / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism / Q000502:physiology*; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000378:metabolism; D007399:Interphase / Q000276:immunology; D009000:Monocytes / Q000166:cytology* / Q000378:metabolism / Q000502:physiology; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000378:metabolism / Q000502:physiology*; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin / Q000096:biosynthesis; D015398:Signal Transduction / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology* / Q000378:metabolism / Q000502:physiology; D018418:Th2 Cells / Q000166:cytology / Q000378:metabolism / Q000502:physiology
C097240:15-deoxy-delta(12,14)-prostaglandin J2; D018925:Chemokines; D006131:Growth Inhibitors; D007155:Immunologic Factors; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D018664:Interleukin-12; D015230:Prostaglandin D2; C036293:prostaglandin D2 receptor